Les médicaments Ozempic, Wegovy et Mounjaro, originellement pour le diabète, suscitent de grands espoirs pour les patients ...
Novo Nordisk (NVO) on Wednesday announced plans to launch some doses of its oral GLP-1 receptor agonist semaglutide under the brand name Ozempic pill in Q2 2026, following a successful commercial ...